Complete an IRB-approved research study in Q2 2023
Commercialization of BRAIN AGE™ in Q4 2023
TORONTO, Jan. 31, 2023 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) is an artificial intelligence-driven digital health company focused on improving brain health. , today develops and commercializes BRAIN AGE™, a proprietary electroencephalogram-based (“EEG”) artificial intelligence solution for detecting and monitoring brain age in individuals, as a potential brain health solution for athletes. Updates on plans and expected milestones in 2023. Diagnosed with mental health and a neurodegenerative condition.
“For nearly two years, we have been working to develop a clinical-grade solution for BRAIN AGE™, which has been used by thousands of people working to improve the brain health of over 50 million patients worldwide. It is available in sports, mental health and neurology clinics across the United States,” said Fabio Chianelli, president of DiagnaMed. “BRAIN AGE™ has the potential to become the only simple and affordable solution for licensed professionals to detect and monitor brain age in patients. It will be available in clinics in
development update
We have entered into an exclusive worldwide licensing agreement with Drexel University for BRAIN AGE™ intellectual property. Additionally, it has begun late-stage development under a sponsored research agreement led by Dr. John Kounios, Professor of Psychology and Brain Sciences at Drexel University. Current development of BRAIN AGE™ integrates its software components into an integrated turnkey pipeline, develops standardized EEG recording protocols, collects new EEG data from ongoing research studies, and updates the latest data The focus is on validating BRAIN AGE™ machine learning using .US Regulatory Market Approval Model
Anticipated Milestones and Market Opportunities
In Q2 2023, the company will complete an IRB-approved research study evaluating the stability and reliability of BRAIN AGE™ in 100 subjects and complete the headset, software and brain age estimation module It’s a schedule. If this is completed and successful, the company aims to obtain regulatory approval to market his BRAIN AGE™ as a clinical tool in the United States by the fourth quarter of 2023.
Commercialization and market opportunities
The company is gearing up to build a BRAIN AGE™ clinical provider network, comprising up to 10,000 licensed physicians, professionals (mental health, neurology) and It consists of a sports clinic. Provided to eligible patients. We believe the potential initial target market population for BRAIN AGE™, consisting of athletes, mental health and neurodegenerative patients, is at least 50 million in the United States alone.
almost Brain Age™
Brain age is now detected by a variety of techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET). Both are expensive, complex, time consuming, unscalable, intimidating, and require a large amount of space to operate. EEG, which measures electrical activity in the brain, shows promise with the development of the next generation of miniaturized EEG headsets. However, using EEG requires advanced and validated machine learning algorithms that precisely place nodules on a person’s head and analyze the data to predict brain age.
BRAIN AGE™ offers an alternative solution to MRI and PET scans. BRAIN AGE™ combines a proprietary 16-channel wearable EEG headset with machine learning technology to assess whether an individual’s brain is aging faster or slower than healthy individuals. This method offers a window into general brain health by detecting the combined effects of physiological, pathological, genetic, environmental, and lifestyle factors that influence the rate of brain aging. increase. Some people’s brains function like they are older than their chronological age. Other people’s brains work as if they were young. The difference between chronological age and brain age is called brain age gap. Understanding how the brain ages is thought to be important for understanding and diagnosing age-related neurological disorders and mental health conditions so that they can be detected, monitored and treated early. BRAIN AGE™ is important for understanding how neurological disorders, brain injuries, and environmental insults prematurely age the brain, and how specific interventions and lifestyles can sustain or strengthen the brain. resource. BRAIN AGE™ is intended to be affordable, easy-to-use, patient-compliant and available in physician’s offices and specialized sports, mental health and neurology clinics worldwide.
About DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. (CSE: DMED) is an artificial intelligence-driven digital health company focused on improving brain health for mental health and neurodegenerative diseases. The Company develops BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an individual’s brain age for clinical and home use.Click here for details DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
Board chairman
Diagnomed Holdings
Phone: 416-800-2684
Email: info@diaagnamed.com
Website: www.dianamed.com
Neither the Canadian Stock Exchange nor its regulatory service providers have reviewed and are not responsible for the adequacy or accuracy of this release.
Notes
Certain statements in this news release, including statements regarding future plans and other matters, are forward-looking statements. Forward-looking statements consist of statements that are not purely historical, including statements regarding beliefs, plans, expectations or intentions regarding the future. Such information is generally forward-looking statements such as “may,” “expect,” “estimate,” “expect,” “intend,” “believe,” “continue,” or It can be identified using its negative form, or similar variations. Readers are cautioned that the assumptions used in preparing the forward-looking information may prove to be incorrect. Actual results may differ materially from those projected due to events and circumstances. It is the result of a number of known and unknown risks, uncertainties and other factors, many of which are beyond our control and which govern business, economic, capital market conditions and operating expenses. ability to do so, and reliance on key personnel. Such statements and information are based on our current and future business strategies and a number of assumptions regarding the environment in which we will operate in the future, our anticipated costs and our ability to achieve our objectives. Factors that could cause actual results to differ materially from forward-looking statements include the continued availability of capital and funds, litigation, the failure of counterparties to meet their contractual obligations and key employees. and the loss of consultants, the general economy, the market, and so on. or business terms. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are set forth under the caption “Risk Factors” in DiagnaMed’s final prospectus dated October 26, 2022. www.sedar.com. Any forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, we disclaim any intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor does it constitute an offer, solicitation or sale in any state, state, province or jurisdiction where such offer, solicitation or sale was previously illegal. does not constitute Registration or eligibility under the securities laws of any such state, state, territory or jurisdiction.
